Kuhnert B R, Gross T L, Kuhnert P M, Erhard P, Brashar W T
Clin Pharmacol Ther. 1986 Dec;40(6):656-64. doi: 10.1038/clpt.1986.241.
The purpose of this study was to add to the limited information available regarding the pharmacology of ritodrine in the peripartum period when treatment fails and labor is not inhibited. Plasma or urine samples from eight parturients and 13 infants were studied; in addition plasma samples at delivery were obtained from a total of 26 mothers and infants. All the mothers received ritodrine in the 24 hours before delivery. Plasma and urine ritodrine (free and conjugated) were determined with HPLC by electrochemical detection. In maternal plasma, an apparent rapid distribution phase with a t1/2 of 32 +/- 21 minutes was followed by a prolonged equilibrium phase with a t1/2 of 17 +/- 10 hours. Seventy-six percent of the ritodrine excreted by the mother was in the form of a conjugate. Ninety percent of the ritodrine excreted by the neonate was also excreted in the form of a conjugate.
本研究的目的是补充关于利托君在围产期治疗失败且未抑制分娩时的药理学方面有限的可用信息。研究了8名产妇和13名婴儿的血浆或尿液样本;此外,还从总共26对母婴的分娩时获取了血浆样本。所有母亲在分娩前24小时内均接受了利托君治疗。采用高效液相色谱电化学检测法测定血浆和尿液中的利托君(游离型和结合型)。在母体血浆中,出现一个表观快速分布相,半衰期为32±21分钟,随后是一个延长的平衡相,半衰期为17±10小时。母亲排泄的利托君中有76%为结合型。新生儿排泄的利托君中90%也以结合型形式排泄。